{"filing":{"accession_number":"0000939767-26-000108","cik":"0000939767","ticker":"EXEL","company_name":"EXELIXIS, INC.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-10","primary_document":"exel-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976726000108/exel-20260910.htm"},"events":[{"id":32803,"run_id":30158,"accession_number":"0000939767-26-000108","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The FDA extended the review period for Exelixis' NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months to March 3, 2027, following submission of updated safety and efficacy data deemed a major amendment. This is a material regulatory milestone affecting the timeline for a potential product approval, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other named event types. It is clearly operational/regulatory in nature and material to investors assessing the company's pipeline progress.","company_name":"EXELIXIS, INC.","ticker":"EXEL","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36068,"accession_number":"0000939767-26-000108","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The FDA extended the review period for Exelixis' NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months to March 3, 2027, following submission of updated safety and efficacy data deemed a major amendment. This is a material regulatory milestone affecting the timeline for a potential product approval, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other named event types. It is clearly operational/regulatory in nature and material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:01:48.302590+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36068,"accession_number":"0000939767-26-000108","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The FDA extended the review period for Exelixis' NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer by three months to March 3, 2027, following submission of updated safety and efficacy data deemed a major amendment. This is a material regulatory milestone affecting the timeline for a potential product approval, but does not fit the specific categories of earnings release, M\u0026A activity, impairment, or other named event types. It is clearly operational/regulatory in nature and material to investors assessing the company's pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:01:48.302590+00:00","company_name":"EXELIXIS, INC.","ticker":"EXEL","filing_date":"2026-09-11"}]}